DECRYPTION – Combining next-generation hormone therapy with standard therapy greatly improves prognosis. A radioactive molecule has been shown to be very effective against the most resistant forms.
With around 50,000 cases per year, prostate cancer represents a quarter of male cancers in France. “If today most of the localized forms are treated well, the prognosis is less good when metastases are present from the outset., details the Pr Karim Fizazi, medical oncologist at the Gustave-Roussy Institute in Paris. This situation affects around 10% of prostate cancer diagnoses.“ This makes it the second leading cause of cancer death in humans.
But the situation is changing. Long powerless, since 2015 doctors have benefited from a series of therapeutic advances that have significantly improved the management of these metastatic cancers. And the momentum continues: at the largest annual oncology conference (organized June 4-8 by Asco, the American Society of Clinical Oncology), researchers presented the very positive results of two new clinical trials.
Progression free survival is more than doubled, which is really great news.
Prof. Karim Fizazi, oncologist at the Institut Gustave-Roussy in Paris
The PEACE-1 academic trial (conducted by the group
This article is for subscribers only. You have 81% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
Already subscribed? Log in